9,249 Shares in IQVIA Holdings Inc. $IQV Purchased by Wealthfront Advisers LLC

Wealthfront Advisers LLC acquired a new position in IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 9,249 shares of the medical research company’s stock, valued at approximately $1,787,000.

Several other large investors also recently bought and sold shares of IQV. Meeder Advisory Services Inc. acquired a new position in shares of IQVIA during the second quarter valued at approximately $404,000. Meeder Asset Management Inc. acquired a new stake in shares of IQVIA in the second quarter worth approximately $45,000. Citizens Financial Group Inc. RI purchased a new stake in shares of IQVIA during the second quarter worth approximately $605,000. MidFirst Bank acquired a new position in IQVIA in the 2nd quarter valued at $174,000. Finally, BlackRock Inc. purchased a new position in IQVIA in the 2nd quarter valued at $2,811,292,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Up 3.0%

NYSE IQV opened at $256.66 on Friday. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $260.30. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The business’s fifty day simple moving average is $211.74 and its 200-day simple moving average is $187.01. The firm has a market cap of $42.25 billion, a PE ratio of 31.84, a P/E/G ratio of 2.12 and a beta of 1.18.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. During the same quarter in the prior year, the firm posted $2.81 earnings per share. IQVIA’s quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its board has approved a share buyback plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. William Blair raised shares of IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. Barclays reissued an “overweight” rating on shares of IQVIA in a research note on Tuesday, July 28th. Mizuho upped their price objective on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. JPMorgan Chase & Co. increased their price objective on shares of IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Finally, TD Cowen raised their target price on shares of IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $241.88.

Insider Activity

In other news, insider Keriann Cherofsky sold 558 shares of IQVIA stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the sale, the insider owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. The trade was a 15.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric Sherbet sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the completion of the transaction, the insider owned 20,999 shares in the company, valued at $5,232,110.84. This represents a 19.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 12,913 shares of company stock worth $3,098,793 over the last quarter. 1.70% of the stock is currently owned by corporate insiders.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.